Influenza virus vaccine Agrippal S1 - Seqirus

Drug Profile

Influenza virus vaccine Agrippal S1 - Seqirus

Alternative Names: Agrippal S1; Begripal; Chiroflu; Sandovac; Subunit-influenza-virus-vaccine; Trivalent subunit inactivated influenza virus vaccine

Latest Information Update: 31 Aug 2016

Price : $50

At a glance

  • Originator Novartis; Novartis Vaccines
  • Developer Seqirus
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 29 Aug 2016 Influenza virus vaccine Agrippal S1 licensed to PaxVax in Switzerland
  • 25 Aug 2016 Sandovac® licensed to Valneva for marketing in Austria
  • 09 Nov 2015 CSL’s influenza vaccine business started operating under the brand name Seqirus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top